Neuboron Therapy System Ltd., Xiamen, Fujian, People's Republic of China.
National Tsing Hua University, Hsinchu, 30013, Taiwan, Republic of China.
Sci Rep. 2023 Sep 21;13(1):15701. doi: 10.1038/s41598-023-42508-0.
NeuMANTA is a new generation boron neutron capture therapy (BNCT)-specific treatment planning system developed by the Neuboron Medical Group and upgraded to an important feature, a Hounsfield unit (HU)-based material conversion algorithm. The range of HU values was refined to 96 specific groups and established corresponding to tissue information. The elemental compositions and mass densities have an important effect on the calculated dose distribution. The region of interest defined in the treatment plan can be converted into multiple material compositions based on HU values or assigned specified single material composition in NeuMANTA. Different material compositions may cause normal tissue maximum dose rates to differ by more than 10% in biologically equivalent doses and to differ by up to 6% in physically absorbed doses. Although the tumor has a lower proportion of BNCT background dose, the material composition difference may affect the minimum dose of biologically equivalent dose and physically absorbed dose by more than 3%. In addition, the difference in material composition could lead to a change in neutron moderation as well as scattering. Therefore, the material composition has a significant impact on the assessment of normal tissue side effects and tumor control probability. It is essential for accurate dose estimation in BNCT.
NeuMANTA 是新一代硼中子俘获治疗(BNCT)专用治疗计划系统,由 Neuboron 医疗集团开发,并升级了一个重要功能,即基于亨氏单位(HU)的材料转换算法。HU 值的范围被细化为 96 个特定组,并与组织信息相对应。元素组成和质量密度对计算剂量分布有重要影响。在治疗计划中定义的感兴趣区域可以根据 HU 值转换为多种材料组成,或者在 NeuMANTA 中指定特定的单一材料组成。不同的材料组成可能导致在生物等效剂量下正常组织最大剂量率差异超过 10%,在物理吸收剂量下差异超过 6%。尽管肿瘤的 BNCT 背景剂量比例较低,但材料组成的差异可能会导致生物等效剂量和物理吸收剂量的最小剂量差异超过 3%。此外,材料组成的差异可能会导致中子慢化和散射的变化。因此,材料组成对正常组织副作用和肿瘤控制概率的评估有重大影响。这对于 BNCT 中的准确剂量估计至关重要。